Ballerup, Denmark, 5 March 2025 - At LEO Pharma’s Annual General Meeting 5 March 2025, Liisa Hurme, President and CEO of Orion Corporation, and Mark Levick, former EU medicines regulator and CEO of Alvotech, were elected as independent members of the Board of Directors.

Liisa Hurme brings over 20 years of experience in the chemical and healthcare industries, with expertise in R&D, business development, global supply chains, and operations. She joined Orion Corporation in 1999 and became President and CEO in 2022. Liisa also chairs the Board at the Chemical Industry Federation of Finland and has served on various company and industry boards. She holds a doctorate in biochemistry from the University of Helsinki.

Mark Levick is a former EU medicines regulator and CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. His expertise was gained through a successful career as a practicing specialist physician in Australia and the UK, before leading global R&D groups at GlaxoSmithKline and Novartis in the UK, US, Switzerland and Iceland. Mark is also member of the Board at InterAx, a Swiss biotech company that uses artificial intelligence and human cell-based pharmacology to develop innovative medicines.

Jesper Brandgaard, Chairman of LEO Pharma’s Board of Directors, said: “Liisa Hurme and Mark Levick both have a long background in senior roles within the pharmaceutical industry, with a track record of impressive results. Liisa’s extensive experience in R&D, business development, and global operations will significantly enhance our board's competencies and support our long-term strategy. Mark's experience in delivering biotech programs for infectious, immunological, and inflammatory diseases, resulting in numerous marketing approvals, makes him an ideal fit as Chair of the Innovation Committee. I am looking forward to working with Liisa and Mark as we continue to advance the exciting developments at LEO Pharma.”

Both Liisa Hurme and Mark Levick will be considered independent members of LEO Pharma's Board of Directors.